Ravi Radhakrishnan | |
---|---|
Born | |
Nationality | Indian |
Citizenship | American |
Occupation(s) | Engineer and academic |
Known for | Biomedical engineering applications |
Academic background | |
Education | B.Tech., Chemical Engineering Ph.D., Chemical Engineering |
Alma mater | Indian Institute of Technology Cornell University |
Academic work | |
Institutions | University of Pennsylvania |
Ravi Radhakrishnan is an American engineer and an academic. He is the Herman P. Schwan Chair of Bioengineering as well as a professor in the Department of Chemical and Biomolecular Engineering at the University of Pennsylvania. [1]
Radhakrishnan's work is centered around creating digital models for biomedical engineering applications,particularly in cancer treatment and nanomedicine. His work has also focused on computational algorithms across molecular and cellular scales,using machine learning,AI,statistical mechanics,and high-performance scientific computing on parallel architectures. His works have been published in academic journals,including Journal of Physics:Condensed Matter and Nature . [2]
Radhakrishnan completed his B.Tech in Chemical Engineering from the Indian Institute of Technology in 1995. He later obtained his Ph.D. in Chemical Engineering from Cornell University in 2001. [3]
Radhakrishnan began his academic career in 2004 at the University of Pennsylvania. From 2004 to 2010,he held concurrent appointments as an assistant professor of bioengineering and chemical and biomolecular engineering in the School of Engineering and Applied Sciences. From 2006 to 2010,he also served as an assistant professor of biochemistry and biophysics in the School of Medicine. In 2010,he was promoted to associate professor of bioengineering and chemical and biomolecular engineering,holding these appointments until 2012. Between 2013 and 2015,he held appointments as an associate professor of chemical and biomolecular engineering and bioengineering. Since 2015,he has held joint primary appointments as a professor in the Department of Chemical and Biomolecular Engineering and as a professor of bioengineering in the School of Engineering and Applied Sciences at University of Pennsylvania. [1]
As one of the founding members,Radhakrishnan also held an appointment as the director of the Penn Institute for Computational Science from 2019 to 2020. Since 2020,he has chaired the Department of Bioengineering,and since 2024,he has held the title of Herman P. Schwan Chair of Bioengineering. [1]
Radhakrishnan's research interests include nanobiotechnology,molecular systems biology,statistical mechanics,multiscale modeling,insilico oncology and systems pharmacology. Investigating phase separation and phase equilibria in porous materials,his 1999 study highlighted a solid understanding of pure adsorbates in simple geometries,and called for advanced models to address complex geometries,chemical and geometrical heterogeneity,and the largely unexplored phase separation in mixtures. [4] In 2004,he co-authored a paper with T Schlick. The paper used transition path sampling to uncover the atomic and energetic details of the conformational changes in DNA polymerase βthat precede nucleotide incorporation,identified key residues and cooperative dynamics crucial for the enzyme's function and fidelity,and provided a protocol applicable to other biomolecular reactions. [5] His 2006 collaborative study with C Alba-Simionesco investigated how confinement within various porous materials influenced the freezing,melting,and structural properties of adsorbates,highlighting new surface-driven and confinement-driven phases,as well as the effects on the glass transition. [6]
Radhakrishnan's 2010 paper investigated ErbB3/HER3 kinase activity,revealing its capacity for autophosphorylation and ATP binding despite structural differences,suggesting its role in signaling pathways and its potential as a therapeutic target in cancer. [7] Later,his 2014 study investigated the prevalence,prognostic significance,and therapeutic implications of ALK mutations in neuroblastoma,highlighting their association with poorer survival and potential for personalized treatment strategies based on mutation profiles. [8] Moreover,in 2018,he analyzed how metastatic melanomas utilized exosomal PD-L1,influenced by IFN-γ,to suppress CD8 T cell function,correlating levels with patient response to anti-PD-1 therapy and suggesting exosomal PD-L1 as a potential biomarker. [9] In 2023,he explored how extracellular matrix stiffness promoted tumor progression by stimulating exosome secretion from cancer cells via an Akt-Rab8 pathway,and demonstrated that exosomes derived under these conditions enhanced tumor growth and activated Notch signaling in recipient cells,indicating a pivotal role for mechanical cues in regulating the tumor microenvironment. [10]
Non-small-cell lung cancer (NSCLC),or non-small-cell lung carcinoma,is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class,NSCLCs are relatively insensitive to chemotherapy,compared to small-cell carcinoma. When possible,they are primarily treated by surgical resection with curative intent,although chemotherapy has been used increasingly both preoperatively and postoperatively.
The Max Planck Institute for Medical Research in Heidelberg,Germany,is a facility of the Max Planck Society for basic medical research. Since its foundation,six Nobel Prize laureates worked at the Institute:Otto Fritz Meyerhof (Physiology),Richard Kuhn (Chemistry),Walther Bothe (Physics),AndréMichel Lwoff,Rudolf Mößbauer (Physics),Bert Sakmann and Stefan W. Hell (Chemistry).
Biomolecular engineering is the application of engineering principles and practices to the purposeful manipulation of molecules of biological origin. Biomolecular engineers integrate knowledge of biological processes with the core knowledge of chemical engineering in order to focus on molecular level solutions to issues and problems in the life sciences related to the environment,agriculture,energy,industry,food production,biotechnology and medicine.
Receptor tyrosine-protein kinase erbB-3,also known as HER3,is a membrane bound protein that in humans is encoded by the ERBB3 gene.
Serine/threonine-protein kinase PLK4 also known as polo-like kinase 4 is an enzyme that in humans is encoded by the PLK4 gene. The Drosophila homolog is SAK,the C. elegans homolog is zyg-1,and the Xenopus homolog is Plx4.
William E. Bentley is the Robert E. Fischell Distinguished Professor of Engineering,founding Director of the Fischell Institute for Biomedical Devices,and currently the Director of the Maryland Technology Enterprise Institute in the A. James Clark School of Engineering at the University of Maryland. He was previously the Chair of the Fischell Department of Bioengineering,where he assisted in establishing the department and provided leadership that led to its nationally ranked status.
Jindřich Henry Kopeček was born in Strakonice,Czech Republic,as the son of Jan and Herta Zita (Krombholz) Kopeček. He is distinguished professor of pharmaceutical chemistry and distinguished professor of biomedical engineering at the University of Utah in Salt Lake City,Utah. Kopeček is also an honorary professor at Sichuan University in Chengdu,China. His research focuses on biorecognition of macromolecules,bioconjugate chemistry,drug delivery systems,self-assembled biomaterials,and drug-free macromolecular therapeutics.
Keith E. Gubbins is a British-born American chemical engineer who is the W.H. Clark Distinguished University Professor of Chemical Engineering at North Carolina State University in Raleigh,North Carolina. He is perhaps best known as one of the originators of statistical associating fluid theory (SAFT).
Pembrolizumab,sold under the brand name Keytruda,is a humanized antibody,more specifically a PD-1 Inhibitor,used in cancer immunotherapy that treats melanoma,lung cancer,head and neck cancer,Hodgkin lymphoma,stomach cancer,cervical cancer,and certain types of breast cancer. It is administered by slow intravenous injection.
Atezolizumab,sold under the brand name Tecentriq among others,is a monoclonal antibody medication used to treat urothelial carcinoma,non-small cell lung cancer (NSCLC),small cell lung cancer (SCLC),hepatocellular carcinoma and alveolar soft part sarcoma,but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized,engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
In condensed matter physics,a confined liquid is a liquid that is subject to geometric constraints on a nanoscopic scale so that most molecules are close enough to an interface to sense some difference from standard bulk liquid conditions. Typical examples are liquids in porous media,gels,or bound in solvation shells.
Entrectinib,sold under the brand name Rozlytrek,is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI),of the tropomyosin receptor kinases (TRK) A,B and C,C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).
Rohit Pappu is an Indian-born computational and molecular biophysicist. He is the Gene K. Beare Distinguished Professor of Engineering and the director of the Center for Biomolecular Condensates (CBC) at Washington University in St. Louis.
Nancy Allbritton is a Professor of Bioengineering and the Frank &Julie Jungers Dean of the College of Engineering at the University of Washington. She was previously a Kenan Professor and Chair in the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University.
Teresa Lyn Head-Gordon is an American chemist and the Chancellor's Professor of Chemistry,Bioengineering,and Chemical and Biomolecular Engineering at the University of California,Berkeley. She is also a faculty scientist in the Chemical Sciences Division at the Lawrence Berkeley National Laboratory and a fellow of both the American Institute for Medical and Biological Engineering and the American Chemical Society (ACS).
A. Thomas Look is Professor of Pediatrics at Harvard Medical School and Vice-Chair for Research,Pediatric Oncology,Dana–Farber Cancer Institute. He is a pioneer in the use of zebrafish in cancer research and made major contributions to the understanding of leukemia and neuroblastoma biology and pathogenesis.
Brian T. Cunningham is an American engineer,researcher and academic. He is a Donald Biggar Willett Professor of Engineering at University of Illinois at Urbana-Champaign. He is a professor of Electrical and Computer Engineering,and a professor of bioengineering.
Andre Francis Palmer is an American engineer who is the Associate Dean for research in the College of Engineering and the Fenburr Ohio Eminent Scholar and Professor of Chemical and Biomolecular Engineering at Ohio State University. He is an expert on hemoglobin-based oxygen carriers and biomaterials used in transfusion medicine.
George Jackson,,,is a British professor of chemical physics in the Department of Chemical Engineering at Imperial College London. He is noted for developing molecular models that describe the thermodynamic properties of complex fluids;as one of the developers of statistical associating fluid theory (SAFT);and for his work in molecular systems engineering. His theoretical work has found a wide range of practical applications in industries such as gas extraction and emerging fields like carbon capture and storage.
Ashutosh Chilkoti is an Indian American biomedical engineer,academic,researcher and serial entrepreneur. He is the Alan L. Kaganov Professor of Biomedical Engineering and Senior Associate Dean in the Pratt School of Engineering at Duke University.